Navigation Links
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
Date:6/29/2009

may be many years before it develops from one stage to the next and most people, with appropriate treatment, never progress beyond the early stages of the disease.

About Clearazide

Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoriasis and alopecia areata and has a rich history of use in dermatology dating back to the 1950s. To date, topical nitrogen mustard has only been available through unapproved and pharmacy compounded products, creating significant access and payment issues for many patients. Clearazide is a proprietary, cosmetically-elegant topical formulation of nitrogen mustard that is made under strict pharmaceutical manufacturing processes. If approved, it will be available through standard pharmacies and managed care plans.

About Yaupon

Yaupon Therapeutics is a privately held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The company has three products in development, with one compound in pivotal studies, one compound in Phase 2 and additional compounds positioned to enter clinical development in the future. The company's business strategy is to build a highly capital efficient organization that leverages the NIH competitive grant system to offset research expenses and to validate its technology. The model emphasizes strong academic collaborations that lead to the licensing and development of unique products with proof of principle and millions of academic research dollars behind them. To date Yaupon has received over $15 million in government support and over $20 million in venture capital investment.


'/>"/>
SOURCE Yaupon Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced that a supplemental New Drug Application (sNDA) ... (FDA) for the expanded use of BYETTA® (exenatide) injection as ... and/or a thiazolidinedione (TZD) in conjunction with diet and exercise ...
... Santiago de Compostela (USC) have analysed levels of radon, a ... results show that 34% of these schools exceed the limit ... of radon is associated with lung cancer. "Out of ... radon levels in excess of 400 Bequerels/m3 in some of ...
... Screening Services (ESS), announced today that they have ... Professional Background Screeners (NAPBS®) accreditation program and will ... (BSCC) Accredited. "We are so pleased ... that we can instill confidence in our existing ...
Cached Biology Technology:Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 2Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 3Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 4Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 5Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 6Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 734 percent of Galician secondary schools exceed maximum recommended radon levels 2ESS Achieves Accreditation From Background Screening Credentialing Council 2
(Date:10/19/2014)... household electricity access in India over the last ... total carbon emissions growth during that time, according ... Nature Climate Change ., "Energy access is ... aspects of life, including education, communication, and health," ... study. , While increased energy access is widely ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... Researchers from Cleveland Clinic,s Wellness Institute and Harvard University ... sodas is associated with a higher risk of stroke. ... with a lower risk. The study recently ... is the first to examine soda,s effect ...
... surrounding the outside of arteries in humansparticularly the left ... or atherosclerosis, which is the leading cause of death ... the American Heart Association,s Arteriosclerosis, Thrombosis and Vascular Biology ... may help in identifying the molecular culprit, with the ...
... Scientists have identified a link between different strains of ... develop vaccines or drugs against life-threatening cases of the ... is common to many potentially fatal forms of the ... were effective against these severe malaria strains. The ...
Cached Biology News:Study finds soda consumption increases overall stroke risk 2Fat outside of arteries may influence onset of coronary artery disease 2Scientists find Achilles' heel in life-threatening malaria parasites 2
...
... TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) offer ... vitro translations: a single-tube, coupled transcription/translation ... simplify the process and reduce the ... translation results. Standard rabbit reticulocyte lysate ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
Biology Products: